Adalimumab oral - Biora Therapeutics
Alternative Names: BT-001 - Biora Therapeutics; BT-002; PGN-001; PGN-OB1Latest Information Update: 22 Dec 2023
Price :
$50 *
At a glance
- Originator Progenity
- Developer Biora Therapeutics
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Ulcerative colitis
Most Recent Events
- 19 Dec 2023 Biora Therapeutics receives an Issue Notification from the United States Patent and Trademark Office (USPTO) for NaviCap™ Targeted Oral Delivery Platform
- 04 Aug 2023 Biora Therapeutics has patent protection and multiple patents pending for its oral delivery platforms worldwide
- 03 Aug 2023 Biora Therapeutics has patent protection for BioJet™ systemic oral delivery platform in USA